Drugs / TQA3605
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT06990776 | Jul 2025 | chronic hepatitis B virus infection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Withdrawn | No outcome recorded |
| Phase 2 | NCT06644417 | Nov 2024 → Aug 2025 | chronic hepatitis B virus infection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07797231 | Sep 2026 → Sep 2028 expected | chronic hepatitis B virus infection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT06150014 Comparator | Dec 2023 → Dec 2025 overdue | chronic hepatitis B virus infection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQA3605 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06644417 ↗ |
| Known as | TQA3605 tablets | “TQA3605 tablets is core protein allosteric modulators” NCT06990776 ↗ |
| Action | Inhibit | “TQA3605 inhibits viral replication.” NCT06150014 ↗ |
| Route | Oral | “TQA3605 is taken orally 100mg once daily” NCT06150014 ↗ |